上海医药普瑞巴林胶囊获新加坡药品注册证书

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the Singapore Food and Drug Administration for the marketing of Pregabalin capsules, indicating a significant milestone for the company in expanding its product offerings in the international market [1]. Group 1 - The approved Pregabalin capsules are primarily used for treating postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, and neuropathic pain due to spinal cord injury, as well as for adjunctive treatment of epilepsy [1].